Literature DB >> 31201817

Head-to-head comparison of plasma cTnI concentration values measured with three high-sensitivity methods in a large Italian population of healthy volunteers and patients admitted to emergency department with acute coronary syndrome: A multi-center study.

Aldo Clerico1, Andrea Ripoli2, Martina Zaninotto3, Silvia Masotti2, Veronica Musetti2, Marcello Ciaccio4, Rosalia Aloe5, Sara Rizzardi6, Ruggero Dittadi7, Cinzia Carrozza8, Tommaso Fasano9, Marco Perrone10, Antonio de Santis11, Concetta Prontera2, Daniela Riggio12, Cristina Guiotto13, Marco Migliardi13, Sergio Bernardini10, Mario Plebani3.   

Abstract

BACKGROUND: The study aim is to compare cTnI values measured with three high-sensitivity (hs) methods in apparently healthy volunteers and patients admitted to emergency department (ED) with acute coronary syndrome enrolled in a large multicentre study.
METHODS: Heparinized plasma samples were collected from 1511 apparently healthy subjects from 8 Italian clinical institutions (mean age: 51.5 years, SD: 14.1 years, range: 18-65 years, F/M ratio:0.95). All volunteers denied chronic or acute diseases and had normal values of routine laboratory tests. Moreover, 1322 heparinized plasma sample were also collected by 9 Italian clinical institutions from patients admitted to ED with clinical symptoms typical of acute coronary syndrome. The reference study laboratory assayed all plasma samples with three hs-methods: Architect hs-cTnI, Access hs-cTnI and ADVIA Centaur XPT methods. Principal Component Analysis (PCA) was also used to analyze the between-method differences among hs-cTnI assays.
RESULTS: On average, a between-method difference of 31.2% CV was found among the results of hs-cTnI immunoassays. ADVIA Centaur XPT method measured higher cTnI values than Architect and Access methods. Moreover, 99th percentile URL values depended not only on age and sex of reference population, but also on the statistical approach used for calculation (robust non-parametric vs bootstrap).
CONCLUSIONS: Due to differences in concentrations and reference values, clinicians should be advised that plasma samples of the same patient should be measured for cTnI assay in the same laboratory. Specific clinical studies are needed to establish the most appropriate statistical approach to calculate the 99th percentile URL values for hs-cTnI methods.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Cardiac troponins; High-sensitivity methods; Myocardial infarction; Reference population values

Mesh:

Substances:

Year:  2019        PMID: 31201817     DOI: 10.1016/j.cca.2019.06.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  9 in total

Review 1.  Natriuretic Peptides and Troponins to Predict Cardiovascular Events in Patients Undergoing Major Non-Cardiac Surgery.

Authors:  Marco Alfonso Perrone; Alberto Aimo; Sergio Bernardini; Aldo Clerico
Journal:  Int J Environ Res Public Health       Date:  2022-04-24       Impact factor: 4.614

Review 2.  Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).

Authors:  Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2021-10-10       Impact factor: 17.349

3.  Frequency histograms of three high-sensitivity cardiac troponin assays in a reference population.

Authors:  Hanwool Cho; Hyunjung Kim; Jehoon Lee; Soo-Young Kim; Hae Kyung Lee; Hi Jeong Kwon; Yeongsic Kim
Journal:  J Clin Lab Anal       Date:  2022-04-20       Impact factor: 3.124

4.  The assessment of high sensitivity cardiac troponin in patients with COVID-19: A multicenter study.

Authors:  Marco Alfonso Perrone; Federica Spolaore; Massimiliano Ammirabile; Francesco Romeo; Patrizio Caciagli; Ferruccio Ceriotti; Sergio Bernardini
Journal:  Int J Cardiol Heart Vasc       Date:  2021-01-09

5.  Utility of a corticotropin-releasing hormone test to differentiate pituitary-dependent hyperadrenocorticism from cortisol-producing adrenal tumors in dogs.

Authors:  Sachiyo Tanaka; Shuji Suzuki; Asaka Sato; Takahiro Teshima; Akihiro Mori; Toshinori Sako; Aki Tanaka; Yasushi Hara
Journal:  J Vet Intern Med       Date:  2021-12-03       Impact factor: 3.333

6.  Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina.

Authors:  Chiara Caselli; Raffaele De Caterina; Jeff M Smit; Jonica Campolo; Mohammed El Mahdiui; Rosetta Ragusa; Alberto Clemente; Tiziana Sampietro; Aldo Clerico; Riccardo Liga; Gualtiero Pelosi; Silvia Rocchiccioli; Oberdan Parodi; Arthur Scholte; Jhuani Knuuti; Danilo Neglia
Journal:  Sci Rep       Date:  2021-10-20       Impact factor: 4.379

7.  Effect of Outlier Elimination on the 99th Percentile Upper Reference Limits of High-Sensitivity Cardiac Troponin I Assays Based on a Strictly Selected Healthy Reference Population.

Authors:  Sunyoung Ahn; Hyun-Ki Kim; Woochang Lee; Sail Chun; Won-Ki Min
Journal:  Ann Lab Med       Date:  2022-05-01       Impact factor: 3.464

Review 8.  Significance of Cardiac Troponins as an Identification Tool in COVID-19 Patients Using Biosensors: An Update.

Authors:  Yousef Rasmi; Osama F Mosa; Shahriar Alipour; Nadia Heidari; Farzaneh Javanmard; Ali Golchin; Shiva Gholizadeh-Ghaleh Aziz
Journal:  Front Mol Biosci       Date:  2022-02-24

9.  Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study.

Authors:  Jacopo Sabbatinelli; Angelica Giuliani; Anna Rita Bonfigli; Deborah Ramini; Giulia Matacchione; Carla Campolucci; Artan Ceka; Elena Tortato; Maria Rita Rippo; Antonio Domenico Procopio; Marco Moretti; Fabiola Olivieri
Journal:  Cardiovasc Diabetol       Date:  2022-09-10       Impact factor: 8.949

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.